Estadísticas

 array:25 [
  "pii" => "S0211699516300807"
  "issn" => "02116995"
  "doi" => "10.1016/j.nefro.2016.05.016"
  "estado" => "S300"
  "fechaPublicacion" => "2016-11-01"
  "aid" => "229"
  "copyright" => "Sociedad Española de Nefrología"
  "copyrightAnyo" => "2016"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia. 2016;36:713-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6771
    "formatos" => array:3 [
      "EPUB" => 342
      "HTML" => 5573
      "PDF" => 856
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:20 [
      "pii" => "S2013251416301298"
      "issn" => "20132514"
      "doi" => "10.1016/j.nefroe.2016.05.007"
      "estado" => "S300"
      "fechaPublicacion" => "2016-11-01"
      "aid" => "229"
      "copyright" => "Sociedad Española de Nefrología"
      "documento" => "simple-article"
      "crossmark" => 0
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "cor"
      "cita" => "Nefrologia (English Version). 2016;36:713-5"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 3003
        "formatos" => array:3 [
          "EPUB" => 355
          "HTML" => 2079
          "PDF" => 569
        ]
      ]
      "en" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
        "titulo" => "Caution with the use of the new direct acting antivirals in the hepatitis C virus related renal disease"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "713"
            "paginaFinal" => "715"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Precauci&#243;n con el uso de los nuevos antivirales de acci&#243;n directa para el tratamiento del virus de la hepatitis C en pacientes con enfermedad renal asociada"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Antonio Gomis, Martha D&#237;az, Alberto de Lorenzo, Gloria Ruiz-Roso, Fernando Lia&#241;o"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "Antonio"
                "apellidos" => "Gomis"
              ]
              1 => array:2 [
                "nombre" => "Martha"
                "apellidos" => "D&#237;az"
              ]
              2 => array:2 [
                "nombre" => "Alberto"
                "apellidos" => "de Lorenzo"
              ]
              3 => array:2 [
                "nombre" => "Gloria"
                "apellidos" => "Ruiz-Roso"
              ]
              4 => array:2 [
                "nombre" => "Fernando"
                "apellidos" => "Lia&#241;o"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0211699516300807"
          "doi" => "10.1016/j.nefro.2016.05.016"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516300807?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416301298?idApp=UINPBA000064"
      "url" => "/20132514/0000003600000006/v1_201702210030/S2013251416301298/v1_201702210030/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S0211699516300790"
    "issn" => "02116995"
    "doi" => "10.1016/j.nefro.2016.05.015"
    "estado" => "S300"
    "fechaPublicacion" => "2016-11-01"
    "aid" => "228"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia. 2016;36:715-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3929
      "formatos" => array:3 [
        "EPUB" => 372
        "HTML" => 2623
        "PDF" => 934
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Dialysis catheter related bacteriemia by <span class="elsevierStyleItalic">Gordonia rubropertincta</span> and <span class="elsevierStyleItalic">Sputi</span> in two hemodialysis patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "715"
          "paginaFinal" => "716"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Bacteriemia relacionada por <span class="elsevierStyleItalic">Gordonia rubropertincta</span> y <span class="elsevierStyleItalic">Sputi</span> en 2 pacientes en hemodi&#225;lisis"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Laura Salanova Villanueva, Esther Ortega, Borja Quiroga"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Laura Salanova"
              "apellidos" => "Villanueva"
            ]
            1 => array:2 [
              "nombre" => "Esther"
              "apellidos" => "Ortega"
            ]
            2 => array:2 [
              "nombre" => "Borja"
              "apellidos" => "Quiroga"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2013251416301316"
        "doi" => "10.1016/j.nefroe.2016.12.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416301316?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516300790?idApp=UINPBA000064"
    "url" => "/02116995/0000003600000006/v1_201611240148/S0211699516300790/v1_201611240148/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S021169951630087X"
    "issn" => "02116995"
    "doi" => "10.1016/j.nefro.2016.06.001"
    "estado" => "S300"
    "fechaPublicacion" => "2016-11-01"
    "aid" => "236"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia. 2016;36:711-3"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5292
      "formatos" => array:3 [
        "EPUB" => 332
        "HTML" => 3942
        "PDF" => 1018
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director</span>"
      "titulo" => "Neumonitis intersticial subaguda por <span class="elsevierStyleItalic">Mycobacterium bovis</span> tras instilaciones vesicales de bacilo de Calmette-Gu&#233;rin en un trasplante renal"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "711"
          "paginaFinal" => "713"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Subacute interstitial pneumonitis due to <span class="elsevierStyleItalic">Mycobacterium bovis</span> after intravesical bacillus Calmette-Gu&#233;rin instillation in a renal transplant patient"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Fernando Caravaca-Font&#225;n, Marta Cano Meg&#237;as, Matilde S&#225;nchez-Conde, Sandra El&#237;as Trivi&#241;o, Ana Fern&#225;ndez-Rodr&#237;guez, Fernando Lia&#241;o"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Caravaca-Font&#225;n"
            ]
            1 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Cano Meg&#237;as"
            ]
            2 => array:2 [
              "nombre" => "Matilde"
              "apellidos" => "S&#225;nchez-Conde"
            ]
            3 => array:2 [
              "nombre" => "Sandra"
              "apellidos" => "El&#237;as Trivi&#241;o"
            ]
            4 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Fern&#225;ndez-Rodr&#237;guez"
            ]
            5 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Lia&#241;o"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2013251417300032"
        "doi" => "10.1016/j.nefroe.2017.01.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417300032?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021169951630087X?idApp=UINPBA000064"
    "url" => "/02116995/0000003600000006/v1_201611240148/S021169951630087X/v1_201611240148/es/main.assets"
  ]
  "es" => array:14 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director</span>"
    "titulo" => "Precauci&#243;n con el uso de los nuevos antivirales de acci&#243;n directa para el tratamiento del virus de la hepatitis C en pacientes con enfermedad renal asociada"
    "tieneTextoCompleto" => true
    "saludo" => "Sr&#46; Director&#58;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "713"
        "paginaFinal" => "715"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Antonio Gomis, Martha D&#237;az, Alberto de Lorenzo, Gloria Ruiz-Roso, Fernando Lia&#241;o"
        "autores" => array:5 [
          0 => array:4 [
            "nombre" => "Antonio"
            "apellidos" => "Gomis"
            "email" => array:1 [
              0 => "antonio&#46;gomis&#64;salud&#46;madrid&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Martha"
            "apellidos" => "D&#237;az"
          ]
          2 => array:2 [
            "nombre" => "Alberto"
            "apellidos" => "de Lorenzo"
          ]
          3 => array:2 [
            "nombre" => "Gloria"
            "apellidos" => "Ruiz-Roso"
          ]
          4 => array:2 [
            "nombre" => "Fernando"
            "apellidos" => "Lia&#241;o"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Hospital Universitario Ram&#243;n y Cajal&#44; Madrid&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Autor para correspondencia</span>&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Caution with the use of the new direct acting antivirals in the hepatitis C virus related renal disease"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">El virus de la hepatitis C &#40;VHC&#41; y la enfermedad renal cr&#243;nica &#40;ERC&#41; a menudo est&#225;n vinculados&#44; lo que provoca un aumento significativo de la morbimortalidad en estos pacientes&#46; Los nuevos antivirales de acci&#243;n directa &#40;AAD&#41; frente al VHC logran una respuesta eficaz en un corto periodo de tiempo<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a>&#46; Sin embargo&#44; en pacientes con ERC relacionada con el VHC su uso es bastante escaso&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Presentamos una serie de 5 pacientes con ERC y VHC tratados con AAD &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;&#46; Todos los pacientes eran varones&#44; con edades comprendidas entre los 52 y los 57 a&#241;os&#44; con ERC y diferentes grados de proteinuria y microhematuria&#46; Se realiz&#243; biopsia renal solo en un paciente&#44; que fue diagn&#243;stica de glomerulonefritis membranoproliferativa secundaria a vasculitis crioglobulin&#233;mica&#46; En el resto de los pacientes se desestim&#243; la realizaci&#243;n de biopsia renal porque presentaban elevado riesgo de sangrado &#40;trombocitopenia o tratamiento antiagregante&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Cuatro pacientes comenzaron tratamiento con sofosbuvir &#40;SOF&#41; y daclatasvir &#40;DAC&#41;&#44; mientras que el quinto recibi&#243; tratamiento con DAC y simeprevir &#40;SIM&#41;&#46; En todos los pacientes se consigu&#243; negativizaci&#243;n de la carga viral del VHC en un corto periodo de tiempo &#40;14-30 d&#237;as&#41;&#44; pero se produjo una disminuci&#243;n de la funci&#243;n renal&#44; as&#237; como un dr&#225;stico aumento de la proteinuria en los pacientes tratados con el esquema SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DAC&#46; El &#250;nico paciente que hab&#237;a sido biopsiado recibi&#243; tratamiento con esteroides y rituximab &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; 4 dosis&#41; 4 semanas despu&#233;s de comenzar el tratamiento antiviral&#44; con lo que consigui&#243; la recuperaci&#243;n de la funci&#243;n renal y disminuci&#243;n de la proteinuria&#46; El paciente que recibi&#243; tratamiento con el esquema DAC<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>SIM finalmente falleci&#243; como consecuencia de una hemorragia digestiva 3<span class="elsevierStyleHsp" style=""></span>meses despu&#233;s de finalizar el tratamiento&#46; Tres pacientes precisaron ingreso hospitalario durante la terapia antiviral&#58; un paciente por episodio de celulitis grave&#44; otro paciente present&#243; 2<span class="elsevierStyleHsp" style=""></span>episodios de insuficiencia cardiaca y el &#250;ltimo paciente precis&#243; varios ingresos y finalmente precis&#243; inicio de terapia renal sustitutiva mediante hemodi&#225;lisis cr&#243;nica&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">En nuestra serie de casos&#44; la presencia de ERC relacionada con la infecci&#243;n por VHC se confirm&#243; mediante biopsia renal en un solo paciente&#44; y con alta sospecha cl&#237;nica en los otros 4&#46; El tratamiento del VHC es el pilar fundamental&#44; no solo para la infecci&#243;n en s&#237;&#44; sino tambi&#233;n para la ERC asociada&#46; En nuestra experiencia&#44; las nuevas terapias con AAD logran una r&#225;pida disminuci&#243;n de la carga viral pero&#44; al menos en estos pacientes&#44; se observa un aumento importante de la proteinuria y microhematuria&#44; con un notable empeoramiento de la funci&#243;n renal en 4<span class="elsevierStyleHsp" style=""></span>de ellos&#44; uno de los cuales finalmente requiri&#243; inicio de hemodi&#225;lisis&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">Existen 2<span class="elsevierStyleHsp" style=""></span>explicaciones posibles para este fen&#243;meno&#58; la primera ser&#237;a una nefritis intersticial aguda emergente&#44; pero el r&#225;pido incremento de la proteinuria y microhematuria har&#237;an poco probable esta posibilidad&#46; La segunda&#44; y quiz&#225;s la m&#225;s probable&#44; ser&#237;a la exacerbaci&#243;n de la ERC asociada al VHC&#44; por las razones ya expuestas&#46; Lamentablemente no pudimos disponer de biopsia renal confirmatoria en todos los casos&#46; Esta situaci&#243;n podr&#237;a ser debida a una amplificaci&#243;n de los procesos inmunol&#243;gicos implicados&#44; tal y como indica la evoluci&#243;n favorable del &#250;nico paciente con ERC asociada al VHC confirmado mediante biopsia&#44; que fue tratado con rituximab seg&#250;n establecen las recomendaciones cl&#237;nicas actuales<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a>&#46; La falta de confirmaci&#243;n histol&#243;gica en el resto de los pacientes contraindic&#243; el uso de rituximab en estos casos&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">En nuestra experiencia&#44; los nuevos AAD son f&#225;rmacos muy potentes y eficaces para el tratamiento del VHC&#44; pero hemos observado con su uso un empeoramiento parad&#243;jico de la funci&#243;n renal en pacientes con ERC previa&#44; as&#237; como un aumento de la proteinuria y microhematuria&#44; principalmente cuando se utiliza SOF en el esquema terap&#233;utico&#44; un aspecto que deber&#225; ser tenido en cuenta en estudios posteriores&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicto de intereses</span><p id="par0035" class="elsevierStylePara elsevierViewall">Todos los autores declaran no tener ning&#250;n conflito de intereses&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicto de intereses"
        ]
        1 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">1<span class="elsevierStyleHsp" style=""></span>m&#58; 1 mes postratamiento&#59; 2<span class="elsevierStyleHsp" style=""></span>m&#58; 2 meses postratamiento&#59; 3<span class="elsevierStyleHsp" style=""></span>m&#58; 3 meses postratamiento&#59; 4<span class="elsevierStyleHsp" style=""></span>m&#58; 4 meses postratamiento&#59; CKD-EPI&#58; <span class="elsevierStyleItalic">Chronic Kidney Disease Epidemiology creatinine equation</span> &#40;ml&#47;min&#47;1&#44;73&#160;m<span class="elsevierStyleSup">2</span>&#41;&#59; Cr&#58; creatinina plasm&#225;tica &#40;mg&#47;dl&#41;&#59; CV&#58; vasculitis crioglobulin&#233;micas&#59; DAC&#58; daclatasvir&#59; MPGN&#58; glomerulonefritis membranoproliferativa&#59; Pr&#47;Cr orina&#58; ratio prote&#237;na&#47;creatinina en orina &#40;mg&#47;g&#41;&#59; Pre&#58; pretratamiento&#59; SIM&#58; simeprevir&#59; SOF&#58; sofosbuvir&#59; VHB&#58; virus de la hepatitis B&#59; VHC&#58; virus de la hepatitis C&#59; VIH&#58; virus de la inmunodeficiencia humana&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Sexo edad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">VHB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">VIH &#40;s&#237;&#47;no carga viral&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">VHC carga viral &#40;UI&#47;ml&#41; pretratamiento&#47;genotipo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Crioglobulinas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Tiempo de negativizaci&#243;n VHC &#40;d&#237;as&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Biopsia renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Diagn&#243;stico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Pre&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">1<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">2<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">3<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">4<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">1</td><td class="td" title="table-entry  " align="left" valign="top">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">990&#46;670&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Positivas</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">DAC 60<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h SOF 400<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">24</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">S&#237;</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">MPGN 2&#46;<span class="elsevierStyleSup"><span class="elsevierStyleItalic">a</span></span> a CV&#44;</td><td class="td" title="table-entry  " align="left" valign="top">Cr&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CKD-EPI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pr&#47;Cr orina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#46;378<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;244&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">194&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="16" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">2</td><td class="td" title="table-entry  " align="left" valign="top">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;404&#46;259&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Negativas</td><td class="td" title="table-entry  " align="left" valign="top">DAC 60<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">14</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">Cr&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">SOF 400<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CKD-EPI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60; 1&#44;57 log&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pr&#47;Cr orina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;351&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;819&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;260&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="16" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">3</td><td class="td" title="table-entry  " align="left" valign="top">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;593&#46;228&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Negativas</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">DAC 60<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h SOF 400<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">30</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">Cr&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;55&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;91&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;86&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CKD-EPI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60; 1&#44;57 log&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pr&#47;Cr orina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;532&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12&#46;995&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;572&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10&#46;170&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="16" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">4</td><td class="td" title="table-entry  " align="left" valign="top">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">24&#46;976&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Positivas</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">DAC 60<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h SIM 150<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">14</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">Cr&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;71&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CKD-EPI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pr&#47;Cr orina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">148&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">423&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">219&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="16" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">5</td><td class="td" title="table-entry  " align="left" valign="top">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15&#46;240&#46;836&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Positivas</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">DAC 60<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h SOF 400<span class="elsevierStyleHsp" style=""></span>mg&#47;24<span class="elsevierStyleHsp" style=""></span>h</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">15</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">No</td><td class="td" title="table-entry  " align="left" valign="top">Cr&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;03&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;03&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&#44;77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CKD-EPI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">27&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60; 1&#44;57 log&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pr&#47;Cr orina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#46;297&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;110&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&#46;557&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;142&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1258438.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Inicio del tratamiento con rituximab&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evoluci&#243;n de los pacientes tras inicio de tratamiento frente e VHC</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:2 [
            0 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of patients with hepatitis C infection and renal disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Bunchorntavakul"
                            1 => "M&#46; Maneerattanaporn"
                            2 => "D&#46; Chavalittdhamrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "World J Hepatol"
                        "fecha" => "2015"
                        "volumen" => "27"
                        "paginaInicial" => "213"
                        "paginaFinal" => "225"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Theraphy for hepatitis C virus related cryoglobulinemic vasculitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Dammaco"
                            1 => "D&#46; Sansonno"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N England J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "1035"
                        "paginaFinal" => "1045"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/02116995/0000003600000006/v1_201611240148/S0211699516300807/v1_201611240148/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48186"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Cartas al Director"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000003600000006/v1_201611240148/S0211699516300807/v1_201611240148/es/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699516300807?idApp=UINPBA000064"
]